Fall 2: Deadpoint

Fall 2: Deadpoint (titled simply Fall 2 in the UK) is a 2026 American survival thriller directed by Peter and Michael Spierig and written by Jonathan Frank and Scott Mann. It is the sequel to Fall (2022). Lionsgate released it in the US on September 2, 2026.

Jax Hunter (Harriet Slater) is still grieving her sister Shiloh, who died in the first film. To honor her, she and a new friend, Luce (Arsema Thomas), attempt the narrow, rickety planks of Mount Kwan in Thailand. Reviews describe Kwan as a fictional mountain modeled on the real Mount Huashan in China. They hire a local guide, John (Tom Brittney).

Bad weather, collapsing walkways and jagged rusted metal trap the women thousands of feet up. Their grief and their differing attitudes to risk are tested as they fight to survive.

The film is a pulp survival story about confronting fear and loss rather than outrunning them. Jax climbs to reconcile with her dead sister's memory, while Luce wants to follow Shiloh's thrill-seeking example. The film tests both approaches against a mountain that does not care about either. Critics read it mostly as a formula sequel, so its message is more implicit than argued: grief and daring can both turn reckless unless they are paired with survival instinct and trust in other people.

Some critics read the film as a pure action B-movie, comparing it to Die Hard or Cliffhanger without a villain. Others see it as a grief story about sisters. Viewers noted the ending sets up a possible third film.

The film continues a franchise built on fear of heights. Reviews received it as a formulaic sequel, and Wikipedia describes the reception as mixed. Critics compared it to Die Hard 2, Cliffhanger and Resident Evil-style adventures. It was a box office success, grossing $25.6 million on a $3 million budget.

Critics were mixed. Roger Ebert's site gave it 1.5 stars and found it more tedious than tense. Dread Central gave 2/5, and the Radio Times gave 3/5. Metacritic's listing includes a 60 score. Praise went to the vertigo-inducing visuals, the committed lead performances and the tense sequences. Complaints targeted the predictable story, cheap-looking CGI and a drug-running subplot some found inauthentic. Audience reactions ranged from enthusiastic to bored, and some viewers noted it sets up a third film.